Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025
Company to hold a conference call at 8:00 a.m. ET
DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), will hold a conference call on Thursday, November 13, 2025, at 8:00 a.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call.
Pelthos management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:
| Date: Time: Toll Free: International: Conf.ID: | Thursday, November 13, 2025 8:00 a.m. Eastern Time 1-877-451-6152 1-201-389-0879 13756828 |
Webcast:
About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at . Follow Pelthos on and .
Contacts
Investors:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
Media:
KWM Communications
Kellie Walsh
(914) 315-6072
